Bisphosphonates

Bone looks static but is continuously remodeled: osteoclasts dissolve and remove old bone (resorption), and osteoblasts lay down new bone (formation). In a healthy young adult these are balanced. After menopause (estrogen loss) and with age, the osteoclasts outpace the osteoblasts — resorption exceeds formation, bone becomes porous and thin, and the result is osteoporosis with its fragility fractures of the hip, spine, and wrist. To rebuild density, you have to restrain the demolition crew.

That is exactly what a bisphosphonate does. It binds avidly to the hydroxyapatite mineral of bone, concentrating at sites of active resorption. When an osteoclast chews into that bone, it swallows the drug — and the nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) then poison the osteoclast’s mevalonate pathway by blocking farnesyl pyrophosphate synthase, collapsing the cell’s "ruffled border" cytoskeleton and triggering osteoclast apoptosis. With resorption suppressed, formation catches up — bone density rises and fracture risk falls. Because the drug is buried in bone, it has a remarkably long skeletal half-life (years) — the rationale for a later "drug holiday."

Here is the fact that drives all the nursing: oral bisphosphonates are barely absorbed — under 1% bioavailability — and that tiny fraction is abolished by any food, calcium, coffee, juice, or mineral water in the stomach. Worse, the drug is directly corrosive to the lining of the esophagus: if a tablet lingers there, it can cause esophagitis, ulcers, and even strictures. Both problems have the same solution, which is why the protocol is non-negotiable. Take the tablet first thing in the morning on an empty stomach, swallow it with a full glass (6–8 oz) of plain water only, then stay upright — sitting or standing — for at least 30 minutes (a full 60 minutes for ibandronate/Boniva) and until after the first food of the day, and wait ≥30 minutes before eating, drinking anything else, or taking any other medication (including calcium, antacids, and vitamins).

Read the protocol as two goals working together. Plain water on an empty stomach + waiting before food rescues the fragile absorption (nothing there to bind the drug). The full glass of water + staying upright washes the tablet down and keeps it from resting against the esophagus — preventing the corrosive injury. Separating from calcium and antacids matters because those cations chelate the drug and destroy what little would be absorbed. Get the protocol right and the drug works safely; get it wrong and you either waste the dose or burn the esophagus.

Beyond the esophagus, three long-horizon risks define the class. Osteonecrosis of the jaw (ONJ) — exposed, non-healing jawbone — is rare with oral osteoporosis doses but rises with IV/high-dose (oncology) use and after invasive dental procedures; the defense is a dental exam before starting and good oral hygiene. Atypical femoral fractures — low-energy breaks of the thigh bone from long-term use — are often heralded by new dull thigh or groin pain, which is the reason to report that symptom and the rationale for a "drug holiday" after ~3–5 years (IV) or 5–10 years (oral) in appropriate patients. And because bisphosphonates lower serum calcium, any hypocalcemia must be corrected before starting, with adequate calcium and vitamin D throughout.

The IV agents add their own two considerations. Zoledronic acid commonly causes a self-limited acute-phase reaction — flu-like fever, myalgia, and arthralgia in the first few days after an infusion (worst after the first dose, treatable with acetaminophen). More seriously, it is renally cleared and nephrotoxic: it is contraindicated when creatinine clearance is below 35 mL/min and in acute renal impairment, so patients must be well hydrated before the infusion and have renal function and calcium checked. None of these carry a class-wide boxed warning, but each is a specific thing the nurse actively teaches and monitors for.